<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04352062</url>
  </required_header>
  <id_info>
    <org_study_id>BMWH-D-20-00081</org_study_id>
    <nct_id>NCT04352062</nct_id>
  </id_info>
  <brief_title>Melatonin Supplementation in Postmenopausal Women With H. Pylori-associated Dyspepsia</brief_title>
  <official_title>The Usefulness of Melatonin Supplementation in Postmenopausal Women With Helicobacter Pylori-associated Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Universtity of Lodz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Universtity of Lodz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: The aim of the study was to assess the role of melatonin in chronic dyspepsia in
      this group of women, with consideration of Helicobacter infection. Methods: The study
      comprised 152 subjects Including 30 healthy women (group I), 60 women with asymptomatic
      H.pylori infection (group II), and 64 women H. pylori infected with chronic dyspepsia(group
      III). Endoscopic examination, histological assessment of gastric end duodenal mucosa, urease
      breath test(UBT-13C), and serum levels of 17-β-estradiol, follicle stimulating hormone,
      melatonin and urinary concentration of 6-sulfatoxymelatonin were determined by
      immunoenzymatic method. In group III - 14-day antibacterial treatment was introduced with
      pantoprazole, amoxicillin and levofloxacin. Afterward, in 32 women was administered
      placebo(group IIIa), and in 32 women (group IIIb) melatonin at a dose 1 m/morning and 3 mg/at
      bedtime, for six months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:Dyspeptic syndrome in the form of epigastric pain are particularly frequent in
      postmenopausal women. The aim of the study was to assess the role of melatonin in chronic
      dyspepsia in this group of women, with consideration of Helicobacter infection. Methods: The
      study comprised 152 subjects Including 30 healthy women (group I), 60 women with asymptomatic
      H.pylori infection (group II), and 64 women H. pylori infected with chronic dyspepsia(group
      III). Endoscopic examination, histological assessment of gastric end duodenal mucosa, urease
      breath test(UBT-13C), and serum levels of 17-β-estradiol, follicle stimulating hormone,
      melatonin and urinary concentration of 6-sulfatoxymelatonin were determined by
      immunoenzymatic method. In group III - 14-day antibacterial treatment was introduced with
      pantoprazole, amoxicillin and levofloxacin. Afterward, in 32 women was administered
      placebo(group IIIa), and in 32 women (group IIIb) melatonin at a dose 1 m/morning and 3 mg/at
      bedtime, for six months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 9, 2011</start_date>
  <completion_date type="Actual">October 26, 2018</completion_date>
  <primary_completion_date type="Actual">October 26, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>10 point Visual Analogue Scale (VAS) of Dyspeptic symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>scale that access severity of Dyspeptic symptoms such as: epigastric pain of hunger nature and pain in the epigastric region at night (intensity measured from 1 to 10 points)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Melatonin Deficiency</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin ( 5-Methoxy-N-Acetyltryptamine) at dose 1mg/morning and 3mg/at bedtime (period 6 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tablet twice daily (period 6 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Helicobacter pylori infected group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pantoprazole 2 x 40mg (twice daily) Amoxicyllin 2 x 1000mg (twice daily) Lovofloxacin 2 x 500mg (twice daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole 40mg</intervention_name>
    <description>pantoprazole 2 x 40mg</description>
    <arm_group_label>Helicobacter pylori infected group</arm_group_label>
    <other_name>Pantoprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Amoxicillin 2 x 1000mg</description>
    <arm_group_label>Helicobacter pylori infected group</arm_group_label>
    <other_name>Amoxycillin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin 500mg</intervention_name>
    <description>Levofloxacin 2 x 500mg</description>
    <arm_group_label>Helicobacter pylori infected group</arm_group_label>
    <other_name>Levofloxacin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with

          -  Epigastric pain of a hunger nature

          -  Pain at night in the epigastric region

          -  Increased appetite

        Exclusion Criteria:

        Patients with

          -  Functional or inflammatory diseases of the gastrointestinal tract liver and pancreas

          -  Metabolic, allergic and mental disease

          -  Hormone replacement therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>49 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cezary Chojnacki, MD.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Nutrition and Gastroenterological Diagnostics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Nutrition and Gastroenterological Diagnostics Medical University of Lodz</name>
      <address>
        <city>Łódź</city>
        <zip>90-647</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Heinemann LA, Potthoff P, Schneider HP. International versions of the Menopause Rating Scale (MRS). Health Qual Life Outcomes. 2003 Jul 30;1:28.</citation>
    <PMID>12914663</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

